Redefining Remission Induction Chemotherapy Ineligibility by Early Mortality in De Novo Acute Myeloid Leukemia

The therapeutic strategies for acute myeloid leukemia (AML) patients ineligible for remission induction chemotherapy have been improving in the past decade. Therefore, it is important to define ineligibility for remission induction chemotherapy. We retrospectively assessed 153 consecutive adult de n...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, You-Cheng, Shih, Yu-Hsuan, Chen, Tsung-Chih, Gau, Jyh-Pyng, Su, Yu-Chen, Chen, Mei-Hui, Hsu, Chiann-Yi, Liao, Cai-Sian, Teng, Chieh-Lin Jerry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708870/
https://www.ncbi.nlm.nih.gov/pubmed/34945065
http://dx.doi.org/10.3390/jcm10245768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708870/
https://www.ncbi.nlm.nih.gov/pubmed/34945065
http://dx.doi.org/10.3390/jcm10245768

Ejemplares similares